Acquired pure megakaryocytic aplasia: a separate haematological disease entity or a syndrome with multiple causes?
We report the case of a patient with acquired pure megakaryocytic aplasia. Until today, less than 20 cases of acquired pure megakaryocytic aplasia have been reported and the disease aetiology still seems to be unclear. This report summarizes the published data concerning possible aetiologies, treatment options and outcome of patients with acquired pure megakaryocytic aplasia. Furthermore, this case report presents an example for a possible disease progression.
Felderbauer
P
P
Department of Medicine I, St Josef-Hospital, Ruhr-University Bochum, Bochum, Germany. peter.felderbauer@ruhr-uni-bochum.de
Ritter
P R
PR
Mattern
D
D
Schmitz
F
F
Bulut
K
K
Ansorge
N
N
Schmitt-Graeff
A
A
Schmidt
W E
WE
Baier
J E
JE
D000328:Adult; D001803:Blood Transfusion; D001855:Bone Marrow Diseases / Q000209:etiology / Q000473:pathology; D001856:Bone Marrow Examination; D016026:Bone Marrow Transplantation / Q000009:adverse effects; D018450:Disease Progression; D017809:Fatal Outcome; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D008297:Male; D008533:Megakaryocytes / Q000473:pathology*; D011693:Purpura; D013921:Thrombocytopenia / Q000209:etiology* / Q000628:therapy; D014184:Transplantation, Homologous; D016896:Treatment Outcome
D007166:Immunosuppressive Agents